Archive · 28 Nov 2025
Cordis Selution Trials Show Positive Results
Cordis, a company that makes tools for heart treatments, shared exciting news about their Selution SLR Drug-Eluting Balloon (DEB).
They did two big tests, called Selution DeNovo and Selution4ISR, to see how well their DEB works compared to the usual treatments for heart problems.
The tests showed that their DEB works just as well as the usual treatments and might be a better choice because it can help doctors use fewer stents.
The DeNovo test had over 3,000 patients from many different places, making it the biggest test of its kind.
This means that Cordis's DEB could be a great new option for treating heart issues.
Cordis announced positive results from Selution DeNovo and Selution4ISR trials at TCT 2025.
Selution SLR DEB met primary endpoints, showing non-inferiority to drug-eluting stents (DES).
Selution DeNovo trial involved 3,323 patients across 62 international sites.
Results suggest Selution SLR DEB could reduce the need for stents in coronary treatments.
Findings highlight Selution SLR DEB as a compelling alternative to current standard treatments.
- Who
- Cordis, a leader in interventional cardiovascular technology
- What
- Announced groundbreaking results from Selution DeNovo and Selution4ISR trials
- When
- At Transcatheter Cardiovascular Therapeutics (TCT) 2025
- Where
- Hyderabad
- Why
- To demonstrate the effectiveness of Selution SLR Drug-Eluting Balloon (DEB) compared to drug-eluting stents (DES)
- Company
- Cordis
- Product
- Selution SLR Drug-Eluting Balloon (DEB)
- Event
- Transcatheter Cardiovascular Therapeutics (TCT) 2025
- Trial 1
- Selution DeNovo
- Trial 2
- Selution4ISR
- Patients in DeNovo Trial
- 3,323
- Sites in DeNovo Trial
- 62